🧬 What Is Immunotherapy for Mesothelioma?

Understanding Immunotherapy for Mesothelioma: From Immune Boost to FDA Approval

Immunotherapy is a treatment that strengthens the body’s own immune system to fight mesothelioma. Instead of attacking cancer cells directly, immunotherapy helps immune cells recognize, target, and destroy mesothelioma tumors more effectively. In 2020, the FDA approved a combination of two immune checkpoint inhibitors—nivolumab (Opdivo) and ipilimumab (Yervoy)—for certain pleural mesothelioma patients.
Source: FDA Approval Notice (CheckMate 743 Trial)

🛠️ When Is Immunotherapy Used? (Purpose & Planning)

Immunotherapy is typically used when standard treatments aren’t effective or as part of a personalized care plan.

Here’s when immunotherapy is typically used:

As first-line treatment for pleural mesothelioma
The Opdivo + Yervoy combination is now approved for patients ineligible for surgery or chemotherapy.

For sarcomatoid or biphasic types
These aggressive cell types respond better to immune-based treatment than chemotherapy.

When surgery isn’t an option
Immunotherapy offers a non-invasive way to slow tumor growth and extend survival.

After chemo or radiation
Used as a follow-up therapy to keep tumors in check or to boost overall response.

In clinical trials
New agents and combinations are continuously tested for all mesothelioma types.

📊 Common Immunotherapy Drugs for Mesothelioma

The most common and effective immunotherapy agents include:

Nivolumab (Opdivo)
A PD-1 checkpoint inhibitor that helps immune cells recognize and fight tumors.

Ipilimumab (Yervoy)
A CTLA-4 inhibitor that activates T-cells to attack mesothelioma cells.

Checkpoint Inhibitor Combo (Opdivo + Yervoy)
Approved by the FDA in 2020 for unresectable pleural mesothelioma, particularly in non-epithelioid cases.

Durvalumab (Imfinzi)
An emerging drug being studied in combination with chemotherapy in several clinical trials.

Other Agents in Trials:
Atezolizumab, Pembrolizumab (Keytruda), and novel immune modulators are being researched.

⚠️ Who Is Eligible for Immunotherapy?

Not all patients qualify for immunotherapy—eligibility depends on:

• Cancer type: Approved for pleural mesothelioma, especially non-epithelioid

• Disease stage: Often used in stage 3 or 4, or when surgery is not viable

• PD-L1 status: High PD-L1 expression may predict better response

• Prior treatments: Can be used after chemotherapy or as a standalone

• Overall health: Immune health must be strong enough to handle activation

Source: CheckMate 743 Study & NCCN Guidelines

🧪 How Immunotherapy Is Delivered

Immunotherapy is usually administered intravenously at infusion centers:

• Infusion Frequency:
  Opdivo is often given every 2 weeks, and Yervoy every 6 weeks in combination protocols.

• Cycle Duration:
  Treatment cycles may continue for up to 2 years, or until disease progression or unacceptable side effects occur.

• Monitoring:
  Patients are monitored regularly with blood tests and imaging to assess response and side effects.

• Outpatient-Based:
  Most infusions take 30–90 minutes and do not require hospital stays.

📈 Effectiveness & Survival Rates With Immunotherapy

Clinical trials show immunotherapy improves survival for some patients:

• Median survival (CheckMate 743): 18.1 months with Opdivo + Yervoy vs. 14.1 months for chemo

• 2-year survival rate: 41% with immunotherapy vs. 27% with chemotherapy

• Better outcomes in non-epithelioid cell types

• Improved quality of life reported in many patients
  Source: NEJM, CheckMate 743 Trial Results

💉 Side Effects & Risks of Immunotherapy

While generally less toxic than chemo, immunotherapy may trigger immune-related side effects:

• Fatigue and low energy

• Skin rashes or itching

• Diarrhea or colitis

• Shortness of breath (pneumonitis)

• Joint or muscle pain

• Endocrine issues (thyroid or adrenal gland)

• Inflammation of lungs, liver, or kidneys (rare but serious)

Most side effects are manageable, but some require stopping treatment or using steroids.

💰 Cost of Immunotherapy for Mesothelioma

Immunotherapy can be expensive, especially when long-term:

• Opdivo + Yervoy (annual): $150,000–$250,000+

• Individual infusions: $10K–$30K per session

• Lab work, scans, and supportive meds: $10K–$25K annually

• Travel and infusion center visits: May increase costs further

Legal compensation or clinical trial participation can ease financial strain.

⚖️ Legal Help for Immunotherapy Patients

If immunotherapy is part of your mesothelioma treatment, and your condition was caused by asbestos exposure, you may qualify for compensation:

• Asbestos Trust Funds – More than $30 billion set aside for victims

• Lawsuits & Settlements – Common payouts of $1M–$2.5M

• VA Benefits – Veterans may receive both treatment and financial aid

• Wrongful Death Claims – Available to families of deceased patients
  MesotheliomaHelp.org – Legal Guide

📚 Lawsuit Examples Involving Immunotherapy

Shipyard Worker — $9.3 Million Verdict (2022)
Details: Diagnosed with non-epithelioid pleural mesothelioma; treated with Opdivo + Yervoy.
Outcome: Manufacturer found liable for asbestos insulation exposure.
Source: Bloomberg Law

Veteran — $10.2 Million Settlement (2021)
Details: Received immunotherapy after years of exposure aboard Navy vessels.
Outcome: VA and civil claims led to joint settlement.
Source: Mealey’s Litigation Report

Textile Mill Worker — $6.8 Million Verdict (2020)
Details: Immunotherapy extended life after biphasic mesothelioma diagnosis.
Outcome: Jury found fabric supplier failed to warn about asbestos.
Source: VerdictSearch

Construction Laborer — $7.5 Million Settlement (2019)
Details: Treated with immunotherapy after diagnosis linked to jobsite dust.
Outcome: Multiple defendants contributed to payout.
Source: Lexis Legal News

Mechanic — $5.9 Million Verdict (2018)
Details: Used Opdivo as part of a clinical trial. Asbestos exposure came from brake dust.
Outcome: Distributor held liable for failure to warn.
Source: National Law Review

🔬 Research and Ongoing Immunotherapy Trials

• DREAM3R Trial: Studying Durvalumab + chemo

• KEYNOTE Studies: Testing Pembrolizumab (Keytruda) for all mesothelioma types

• Checkpoint Inhibitor Expansion: Trials include anti-LAG3 and anti-TIGIT agents

• Tumor Microenvironment Research: Targeting immune suppression mechanisms

Find active studies at: ClinicalTrials.gov

📍 Final Prognosis

Immunotherapy has become a critical tool in treating pleural mesothelioma, especially for patients with aggressive or inoperable tumors. It offers new hope for long-term survival and improved quality of life—with fewer side effects than traditional treatments in many cases.

As research continues, more patients may benefit from targeted immune-based care.

👨‍⚖️ How a Mesothelioma Lawyer Can Help

An experienced attorney can help you:

• Investigate your asbestos exposure timeline

• File claims for compensation related to treatment costs

• Assist with VA applications or appeals

• Represent family members in wrongful death cases

• Charge nothing unless your case is successful

📞 Free Legal Help for Immunotherapy Patients With Mesothelioma

If you or a loved one are receiving immunotherapy for mesothelioma due to asbestos exposure, you may be entitled to major financial compensation.

Call Now: 800.291.0963
• No upfront fees
• No cost unless we win
• Drug and exposure history review included
• Support for workers, veterans, and families

Or request help online 24/7